Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy

Frontiers in Neurology

Volumn 6, Issue SEP, 2015, Pages

  Di Francesco, Jacopo C ^a,b   Longoni, Martina ^a,b   Piazza, Fabrizio ^a,b,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b International Network   (Italy)

^c The iCAß ITALY Study Group of the Italian Society for the Study of Dementia (SINdem)   (Italy)

Author keywords

Alzheimer's disease; Amyloid related imaging abnormalities; Anti amyloid antibody clinical trials; A disease modifying therapies; Cerebral amyloid angiopathy related inflammation; Cerebrospinal fluid biomarker; ICA International Network; Immunotherapy

Indexed keywords

ADUCANUMAB; AMYLOID BETA AUTOANTIBODY; APOLIPOPROTEIN E4; AUTOANTIBODY; BAN 2401; BAPINEUZUMAB; BIOLOGICAL MARKER; CRENEZUMAB; GANTENERUMAB; NOOTROPIC AGENT; PONEZUMAB; SOLANEZUMAB; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID RELATED IMAGING ABNORMALITY E; AMYLOID RELATED IMAGING ABNORMALITY H; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONFUSION; DRUG EFFICACY; DRUG SAFETY; GENE FREQUENCY; GENE MUTATION; HEADACHE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOREACTIVITY; IMMUNOTHERAPY; NEUROPSYCHIATRY; PROTEIN PHOSPHORYLATION; RADIATION INJURY; VASCULAR AMYLOIDOSIS; WHITE MATTER;

EID: 84944742186     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00207     Document Type: Article

References (50)

1. Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol (2015) 11:41-55. doi: 10.1038/nrneurol.2014.232
2. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 7:367-85. doi:10.1016/j.jalz.2011.05.2351
3. Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, et al. MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol (2013) 34(10):1958-65. doi:10.3174/ajnr.A3500
4. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 370:322-33. doi:10.1056/NEJMoa1304839
5. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 73:2061-70. doi:10.1212/WNL.0b013e3181c67808
6. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 11:241-9. doi:10.1016/S1474-4422(12)70015-7
7. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 61:46-54. doi:10.1212/01.WNL.0000073623.84147.A8
8. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2012) 69:198-207. doi:10.1001/archneurol.2011.1538
9. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol (2012) 69:1-12. doi:10.1001/archneurol.2012.2194
10. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 370:311-21. doi:10.1056/NEJMoa1312889
11. Scheltens P. Biomarker Data from SCarlet RoAd-a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD. The Alzheimer's Association International Conference (AAIC) (2015). Available from: https://www.alz.org/aaic/abstracts/abstr-archives.asp
12. Sevigny J. Aducanumab (BIIB037), an Anti-Amyloid Beta Monoclonal Antibody, in Patients with Prodromal or Mild Alzheimer's Disease: Interim Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1B Study. The Alzheimer's Association International Conference (AAIC) (2015). Available from: https://www.alz.org/aaic/abstracts/abstr-archives.asp
13. DiFrancesco JC, Brioschi M, Brighina L, Ruffmann C, Saracchi E, Costantino G, et al. Anti-Abeta autoantibodies in the CSF of a patient with CAA-related inflammation: a case report. Neurology (2011) 76:842-4. doi:10.1212/WNL.0b013e31820e773c
14. Frisoni GB. ARIA from off-key operas? Lancet Neurol (2012) 11:207-8. doi:10.1016/S1474-4422(12)70021-2
15. Greenberg SM, Frosch MP. Life imitates art: anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy. Neurology (2011) 76:772-3. doi:10.1212/WNL.0b013e31820e7bce
16. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, et al. Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol (2013) 73:449-58. doi:10.1002/ana.23857
17. Werring DJ, Sperling R. Inflammatory cerebral amyloid angiopathyand amyloid-modifying therapies:Variations on the same ARIA? Ann Neurol (2013) 73:439-41. doi:10.1002/ana.23891
18. Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke (2015) 17:17-30. doi:10.5853/jos.2015.17.1.17
19. BusinessWire. Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference (2015). Available from: http://www.businesswire.com/news/home/20150320005170/en/Biogen-Idec-Presents-Positive-Interim-Results-Phase#.VS5GktysXE1
20. DiFrancesco JC, Touat M, Caulo M, Gallucci M, Garcin B, Levy R, et al. Recurrence of cerebral amyloid angiopathy-related inflammation: a report of two cases from the iCAβ International Network. J Alzheimers Dis (2015) 46:1071-7. doi:10.3233/JAD-150070
21. Boncoraglio GB, Piazza F, Savoiardo M, Farina L, DiFrancesco JC, Prioni S, et al. Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-abeta autoantibodies. J Alzheimers Dis (2015) 45:363-7. doi:10.3233/JAD-142376
22. Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, et al. Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology (2015) 85(8):692-700. doi:10.1212/WNL.0000000000001877
23. Castro Caldas A, Silva C, Albuquerque L, Pimentel J, Silva V, Ferro JM. Cerebral amyloid angiopathy associated with inflammation: report of 3 cases and systematic review. J Stroke Cerebrovasc Dis (2015) 24(9):2039-48. doi:10.1016/j.jstrokecerebrovasdis.2015.04.015
24. Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol (2004) 55:250-6. doi:10.1002/ana.10810
25. Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology (2007) 68:1411-6. doi:10.1212/01.wnl.0000260066.98681.2e
26. Kirshner HS, Bradshaw M. The inflammatory form of cerebral amyloid angiopathy or "cerebral amyloid angiopathy-related inflammation" (CAARI). Curr Neurol Neurosci Rep (2015) 15:572. doi:10.1007/s11910-015-0572-y
27. Martucci M, Sarria S, Toledo M, Coscojuela P, Vert C, Siurana S, et al. Cerebral amyloid angiopathy-related inflammation: imaging findings and clinical outcome. Neuroradiology (2014) 56:283-9. doi:10.1007/s00234-014-1330-6
28. Mendonca MD, Caetano A, Pinto M, Cruz ESV, Viana-Baptista M. Stroke-like episodes heralding a reversible encephalopathy: microbleeds as the key to the diagnosis of cerebral amyloid angiopathy-related inflammation-a case report and literature review. J Stroke Cerebrovasc Dis (2015) 24(9):e245-50. doi:10.1016/j.jstrokecerebrovasdis.2015.04.042
29. Berkowitz AL, Baker JM, Miller JJ, Greenberg SM. Mystery case: cerebral amyloid angiopathy-related inflammation. Neurology (2014) 83:1678-9. doi:10.1212/WNL.0000000000000930
30. Crosta F, Orlandi B, De Santis F, Passalacqua G, DiFrancesco JC, Piazza F, et al. Cerebral amyloid angiopathy-related inflammation: report of a case with very difficult therapeutic management. Case Rep Neurol Med (2015) 2015:483020. doi:10.1155/2015/483020
31. Raman MR, Wiste HJ, Senjem ML, Ward CP, Jack CR Jr, Kantarci K. Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. Neurology (2014) 83:1771-2. doi:10.1212/WNL.0000000000000957
32. Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, et al. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement (2011) 7:396-401. doi:10.1016/j.jalz.2011.05.2353
33. Chamard L, Wallon D, Pijoff A, Berger E, Viennet G, Hannequin D, et al. Amyloid-related imaging abnormalities in AbetaPP duplication carriers. J Alzheimers Dis (2013) 37:789-93. doi:10.3233/JAD-130629
34. Ryan NS, Lashley T, Revesz T, Dantu K, Fox NC, Morris HR. Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease. J Alzheimers Dis (2014) 44(4):1069-74. doi:10.3233/JAD-142325
35. Floris G, Di Stefano F, Cherchi MV, Costa G, Marrosu F, Marrosu MG. Multiple spontaneous cerebral microbleeds and leukoencephalopathy in PSEN1-associated familial Alzheimer's disease: mirror of cerebral amyloid angiopathy? J Alzheimers Dis (2015) 47:535-8. doi:10.3233/JAD-150165
36. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology (2001) 57:801-5. doi:10.1212/WNL.57.5.801
37. Song MS, Mook-Jung I, Lee HJ, Min JY, Park MH. Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients. J Int Med Res (2007) 35:301-6. doi:10.1177/147323000703500303
38. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 37:943-8. doi:10.1016/S0531-5565(02)00029-3
39. Conti E, Galimberti G, Tremolizzo L, Masetto A, Cereda D, Zanchi C, et al. Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1-42 antibodies in Alzheimer's disease patients. Neurosci Lett (2010) 486:193-6. doi:10.1016/j.neulet.2010.09.050
40. Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, Sassolas A, et al. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett (2004) 355:226-30. doi:10.1016/j.neulet.2003.10.071
41. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol (2001) 49:808-10. doi:10.1002/ana.1061
42. Conti E, Galimberti G, Piazza F, Raggi ME, Ferrarese C. Increased soluble APPalpha, Abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from down syndrome patients. Alzheimer Dis Assoc Disord (2010) 24:96-100. doi:10.1097/WAD.0b013e3181aba63a
43. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med (2003) 3:29-39. doi:10.1385/NMM:3:1:29
44. Bogner S, Bernreuther C, Matschke J, Barrera-Ocampo A, Sepulveda-Falla D, Leypoldt F, et al. Immune activation in amyloid-beta-related angiitis correlates with decreased parenchymal amyloid-beta plaque load. Neurodegener Dis (2014) 13:38-44. doi:10.1159/000352020
45. Hermann DM, Keyvani K, van de Nes J, Weimar C, Wiltfang J, Nitsch RM, et al. Brain-reactive beta-amyloid antibodies in primary CNS angiitis with cerebral amyloid angiopathy. Neurology (2011) 77:503-5. doi:10.1212/WNL.0b013e318227b250
46. Kimura A, Sakurai T, Yoshikura N, Hayashi Y, Takemura M, Takahashi H, et al. Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation. J Neuroinflammation (2013) 10:39. doi:10.1186/1742-2094-10-39
47. Sengoku R, Matsushima S, Murakami Y, Fukuda T, Tokumaru AM, Hashimoto M, et al. (1)(1)C-PiB PET imaging of encephalopathy associated with cerebral amyloid angiopathy. Intern Med (2014) 53:1997-2000. doi:10.2169/internalmedicine.53.1731
48. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 69:1002-10. doi:10.1001/archneurol.2012.90
49. Piazza F, Greenberg SM, Lleó A, Ferrarese C, Nitrini R, Tagliavini F, et al. Anti-Aβ Autoantibodies in CAA and AD: Different Singers for the Same ARIA? Alzheimers Dement (2014) 10(4 Suppl):P221. doi:10.1016/j.jalz.2014.04.304
50. Piazza F. The Inflammatory Cerebral Amyloid Angiopathy and Alzheimer's Disease Biomarkers International Network (2015). Available from: https://sites.google.com/site/icabinternationalnetwork